About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
SGLT2 Inhibitors - A New Class of CV Drugs for the Prevention and Treatment of Cardiovascular Disease
By
The 8th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure
FEATURING
Gregg Fonarow
By
The 8th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure
FEATURING
Gregg Fonarow
1,367 views
January 2, 2019
3 Comments
Login to view comments.
Click here to Login
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Related Content
AUTOPLAY
ON
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments
Primer on Diabetes Management
Feat.
S. Inzucchi
11:37
ACC 2022 Conference Coverage
ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…
Feat.
P. Heidenreich
11:25
ACC 2023 Conference Coverage
ACC 2023: SGLT2i Use - Dos and Don'ts
Feat.
A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention
Diabetes Treatment Guidelines Finally Have Entered the 21st Century …
Feat.
R. DeFronzo
15:06
Robert Busch
GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!
26:01
Cardiology Fiesta 2017
Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…
Feat.
R. DeFronzo
12:26
Juan Frias
SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide
15:33
Ken Fujioka
Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…
17:44
Rita Jermyn
SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease
27:24
Cardiometabolic Health Congress (CMHC)
SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes
Feat.
L. Sloan
20:24
Diana Isaacs
Tirzepatide for Type 2 Diabetes
26:49
Diana Isaacs
Tirzepatide Updates
14:19
UChicago Medicine
S-QUAD Therapy and Beyond: HFpEF in 2024
Feat.
M. Belkin
05:08
Susan Brian
The Differences Between the Products of GLP1's and GLP/GIPs
06:31
Susan Brian
Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist
13:33
Dr. Sharmila Ghimire
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesi…
Feat.
D. Ghimire
19:30
ACC 2022 Conference Coverage
Hot Topics in Heart Failure ACC.22
Feat.
N. Ibrahim
28:02
Barbara Mcgowan
Obesity in the Year 2024
36:34
Scripps Health
GLP-1 Hysteria
Feat.
S. Harris
49:21
McMaster University Department of Medicine
Semaglutide: Where Are We Now and Where Are We Going?
Feat.
S. Boushahri,
D. Lazzam,
K. MacEachern
